Walmart’s Discount Insulin Could Attract Insured Customers

Walmart Inc. — which like Amazon has been diving deeper and deeper into health care — recently made one of its biggest moves yet in that space by partnering with Novo Nordisk to launch private-label insulin at a steeply discounted cash price. While the new offering still may be too expensive for some and likely won’t solve the overarching insulin-affordability problem, some observers say it’s indicative of how well-poised certain companies are to disrupt the health care industry’s least consumer-friendly practices.

“Insulin is, from a business point of view, attractive to competitors like Walmart — they see a product that has a very big audience that is grossly overpriced, where that audience is stressed and dissatisfied because they don’t believe they’re getting the value that they should be getting,” says Michael Abrams, a principal and co-founder at health care consulting firm Numerof & Associates.

About 34 million Americans, or just over 1 in 10, had diabetes as of 2020, according to the Centers for Disease Control and Prevention. The condition comes with estimated medical costs of around $9,601 per year, and the price of insulin has become a particular concern in recent years, with one study finding that the average price of an insulin prescription doubled between 2012 and 2016. Those high costs can be dangerous and even deadly, as news reports and research examining the practice of insulin rationing have illustrated.

© 2025 MMIT
Leslie Small

Leslie Small

Leslie has been working in journalism since 2009 and reporting on the health care industry since 2014. She has covered the many ups and downs of the Affordable Care Act exchanges, the failed health insurer mega-mergers, and hundreds of other storylines spanning subjects such as Medicaid managed care, Medicare Advantage, employer-sponsored insurance, and prescription drug coverage. As the managing editor of Health Plan Weekly and Radar on Drug Benefits, she writes and edits for both publications while overseeing a small team of reporters who also focus on the managed care sector. Before joining AIS Health, she was a senior editor for the e-newsletter Fierce Health Payer, and she started her career as a copy editor at multiple local newspapers. She graduated with a dual degree in journalism and political science from Penn State University.

Related Posts

September 26

News Briefs: Sanders Touts PBM Promise in Pushing for Wegovy, Ozempic Price Cut

READ MORE
republican-and-democratic-party
September 26

Would Red or Blue Election Wins Be Better for PBMs? It’s a Tossup

READ MORE
pharmacist
September 26

Satisfaction With PBM Industry Dips to Record Low in 2024

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today